Clinical Trial Detail

NCT ID NCT03217838
Title Safety, Tolerability, and Efficacy of AZD2811 Nanoparticles in Patients With Relapsed AML/High-Risk Myelodysplastic Syndrome or Treatment-Naïve Patients.
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors AstraZeneca
Indications

acute myeloid leukemia

Therapies

AZD2811

Age Groups: adult senior

No variant requirements are available.